OCUL insider files Form 144 to sell 10,502 shares on NASDAQ
Rhea-AI Filing Summary
Ocular Therapeutix (OCUL) filing a Form 144 notifies the proposed sale of 10,502 common shares with an aggregate market value of $115,889.57. The shares were acquired on 10/01/2025 through restricted stock vesting under a registered plan, and the proposed approximate sale date is 10/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports 173,995,221 shares outstanding for the issuer. It also discloses a recent sale by the same person: 3,063 shares sold on 08/25/2025 for $36,882.81. The filer affirms they are not aware of any undisclosed material adverse information.
Positive
- 10,502 shares were acquired by restricted stock vesting under a registered plan (compensation-related origin)
- Filer affirms no knowledge of undisclosed material adverse information
Negative
- Proposed sale of 10,502 shares with aggregate market value $115,889.57
- Recent prior sale of 3,063 shares on 08/25/2025 for $36,882.81
Insights
TL;DR: Insider plans to sell 10,502 vested shares worth $115,889.57; prior sale of 3,063 shares noted.
The Form 144 shows an insider sale authorization for 10,502 common shares acquired by restricted stock vesting on 10/01/2025, with an approximate sale date of 10/02/2025 via Morgan Stanley Smith Barney LLC.
The filing also records a prior disposition of 3,063 shares on 08/25/2025 that generated $36,882.81 in gross proceeds. The issuer's reported outstanding share count is 173,995,221, which provides context for the scale of these transactions relative to total shares.
FAQ
What does the OCUL Form 144 disclose?
Who is handling the sale in the OCUL Form 144?
Has the insider sold other OCUL shares recently?
How many OCUL shares are outstanding per this filing?
When were the shares to be sold acquired?